Denali Therapeutics Inc. $DNLI Shares Sold by Candriam S.C.A.

Candriam S.C.A. reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 5.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,099,845 shares of the company’s stock after selling 66,534 shares during the quarter. Candriam S.C.A.’s holdings in Denali Therapeutics were worth $21,117,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Headlands Technologies LLC acquired a new position in Denali Therapeutics in the 2nd quarter valued at about $26,000. Johnson Financial Group Inc. purchased a new position in Denali Therapeutics in the 3rd quarter valued at about $29,000. State of Wyoming acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Denali Therapeutics during the 4th quarter worth about $57,000. Finally, Quarry LP purchased a new stake in shares of Denali Therapeutics during the third quarter worth about $64,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on DNLI. Wall Street Zen upgraded shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. The Goldman Sachs Group increased their price target on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on Denali Therapeutics in a report on Friday, May 22nd. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Finally, Stifel Nicolaus set a $41.00 target price on Denali Therapeutics in a research report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.25.

Denali Therapeutics Trading Down 5.6%

DNLI traded down $1.53 during trading on Friday, hitting $25.68. 1,383,081 shares of the company’s stock were exchanged, compared to its average volume of 1,763,467. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. The firm has a market cap of $4.08 billion, a P/E ratio of -8.92 and a beta of 0.96. The stock has a 50 day moving average price of $21.79 and a 200 day moving average price of $20.36. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same period last year, the company earned ($0.78) earnings per share. As a group, analysts expect that Denali Therapeutics Inc. will post -2.77 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.